Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Sudapyridine in Healthy Chinese Subjects
NCT06117514Phase 1Completed
- Sponsor
- Shanghai Jiatan Pharmatech
- Start
- Feb 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sudapyridine in Tuberculosis (TB) (9 arms), sponsored by Shanghai Jiatan Pharmatech. Primary endpoints: Maximum plasma concentration, Time to reach plasma Cmax and 6 more. Started Feb 2019; status: completed.
02
Drugs
sudapyridine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06117514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06117514.